Paclitaxel is a cytostatic (medicine against cancer). Paclitaxel inhibits the growth of cancer cells, finally leading to their extirpation. It may stop cancer cells from dividing and growing.
PACLEX® is used to treat different types of cancer:
–Ovarian cancer: In first line chemotherapy of ovarian cancer, paclitaxel is indicated for the treatment of patients with advanced disease or
a residual disease (> 1cm) after initial laparotomy, in combination with cisplatin. In secondline chemotherapy of ovarian cancer, paclitaxel is indicated in the treatment of metastatic carcinoma of the ovary after failure of standard platinum-based therapy.
–Breast cancer: In the adjuvant setting, paclitaxel is indicated for the treatment of patients with nodepositive breast carcinoma following
anthracycline and cyclophosphamide (AC) therapy. Adjuvant treatment with paclitaxel should be regarded as an alternative to extended AC therapy. Paclitaxel is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who overexpress human epidermal growth factor receptor 2 (HER2) at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. As a single agent, treatment of metastatic carcinoma of the breast in patients who have failed to respond adequately to standard treatment with anthracyclines or in whom anthracycline therapy has not been appropriate.
–Advanced nonsmall cell lung cancer (NSCLC): Paclitaxel, in combination with cisplatin, is indicated for the treatment of patients who are not candidates for potentially curative surgical intervention and/or radiation therapy.
–AIDSrelated Kaposi’s sarcoma (KS): Paclitaxel is indicated for the treatment of patients who have failed prior liposomal anthracycline therapy.